Fig. 4: The management and outcomes of patients with delayed neurotoxicities. | Blood Cancer Journal

Fig. 4: The management and outcomes of patients with delayed neurotoxicities.

From: Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma

Fig. 4

A Timing of toxicities and treatment in patients with IEC-NP. B Timing of toxicities and treatment in patients with IEC-PKS. CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, IEC-NP immune effector cell-associated nerve palsies, IEC-PKS immune effector cell-associated parkinsonism, IVIG intravenous immunoglobulin. CRS (purple bars), ICANS (blue bars), duration with delayed neurotoxicity symptoms (green bars), duration without toxicity (white bars), corticosteroid treatment (yellow triangle), IVIG treatment (yellow diamond in (A)), cyclophosphamide treatment (yellow diamond in (B)), carvidopa/levadopa (yellow square), death (black cross), alive at last follow-up (red circle).

Back to article page